Table 2.
Univariate and multivariate analysis of PFS1.
| characteristics | mPFS1(95%CI) | p value | HR (95%CI) | p Value |
|---|---|---|---|---|
| Age | ||||
| ≤65 | 7.29 (5.72, 10.51) | 0.5423 | — | — |
| >65 | 6.51 (5.45, 10.38) | — | — | |
| Gender | ||||
| Male | 7.16 (5.82, 10.25) | 0.196 | — | — |
| Female | 5.62 (3.42, 10.51) | — | — | |
| Smoking history | ||||
| Never | 8.77 (5.62, 12.42) | 0.7845 | — | — |
| ≤40 pack-years | 6.64 (5.29, 9.66) | — | — | |
| >40 pack-years | 6.67 (5.32, 10.41) | — | — | |
| Therapy | ||||
| Monotherapy | 6.21 (4.83, 10.15) | 0.2582 | — | — |
| Combined chemotherapy | 8.31 (5.82, 11.4) | — | — | |
| Combined anti-angiogenic agents | 3.81 (0.36, 10.51) | — | — | |
| Treatment line | ||||
| First-line | 9.66 (6.51, 12.91) | 0.0303 | ref | |
| Second-line | 5.34 (3.25, 8.77) | 2.33 (1.21,4.47) | 0.011 | |
| Subsequent line | 6.47 (5.22, 10.25) | 1.59 (0.78,3.24) | 0.202 | |
| Stage | ||||
| II/III | 8.64 (5.68, 22.97) | 0.1439 | — | — |
| IV | 6.64 (5.62, 9.66) | — | — | |
| PS | ||||
| 0 | 8.67 (5.75, 10.51) | 0.152 | — | — |
| 1 | 6.67 (5.42, 10.38) | — | — | |
| ≥2 | 2.1 (0.41, 3.8) | — | — | |
| EGFR/ALK/ROS1 mutation | ||||
| No | 9.86 (5.72, 13.24) | 0.0145 | ref | |
| Yes | 6.11 (2.2, 10.64) | 1.12 (0.58,2.15) | 0.73 | |
| PD-L1 expression | ||||
| Negative | 5.72 (4.4, 9.86) | 0.0039 | ref | |
| 1-49% | 5.42 (4.27, 10.51) | 0.91 (0.51,1.61) | 0.746 | |
| ≥50% | 16.39 (10.93, 21.86) | 0.45 (0.21,0.97) | 0.04 | |
| Cancer type | ||||
| Adenocarcinoma | 8.67 (5.52, 12.42) | 0.2613 | — | — |
| Squamous cell lung cancer | 9.13 (6.11, 12.65) | — | — | |
| Small cell lung cancer | 5.68 (4.27, 6.01) | — | — | |
| Other types | 6.67 (5.22, 10.64) | — | — | |